Plain-English translation of NCT06618599 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether combining two pain-relief injection techniques works better than using a single technique to manage pain after lung cancer surgery. The injections use a numbing medication called bupivacaine delivered to specific areas near the spine to block pain signals. Researchers want to see which approach gives patients the best pain relief with the fewest side effects.
After lung cancer surgery, patients often experience significant pain that can slow their recovery. This trial exists to find the most effective pain management strategy, so doctors can help patients heal more comfortably and possibly return to normal activities faster.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would be randomly assigned to receive one of two pain-relief injection approaches before your lung cancer surgery. One group receives two combined injections, while the other receives a single injection—all guided by ultrasound to ensure accuracy. After surgery, your pain levels and recovery would be monitored to compare how well each technique works for managing your discomfort.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Egypt
Sponsor
Cairo University
Enrollment target
~60 participants
Started
October 2024
Primary completion
January 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
sayed M abed, MD degree
Cairo University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.